S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   437.34 (-0.30%)
MSFT   212.46 (-0.39%)
FB   249.95 (+0.05%)
GOOGL   1,480.47 (+0.49%)
AMZN   3,185.69 (+1.49%)
NVDA   450.97 (+0.41%)
CGC   19.17 (-0.78%)
BABA   264.03 (+0.70%)
TSLA   1,485.88 (-0.08%)
MU   50.98 (-0.62%)
GE   6.15 (+0.16%)
AMD   85.43 (+0.46%)
T   29.81 (-0.67%)
F   6.96 (+1.46%)
ACB   10.69 (-0.37%)
GILD   69.47 (-1.99%)
NFLX   503.86 (-1.13%)
DIS   128.25 (+9.34%)
BAC   25.35 (+1.36%)
BA   173.35 (+5.02%)
S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   437.34 (-0.30%)
MSFT   212.46 (-0.39%)
FB   249.95 (+0.05%)
GOOGL   1,480.47 (+0.49%)
AMZN   3,185.69 (+1.49%)
NVDA   450.97 (+0.41%)
CGC   19.17 (-0.78%)
BABA   264.03 (+0.70%)
TSLA   1,485.88 (-0.08%)
MU   50.98 (-0.62%)
GE   6.15 (+0.16%)
AMD   85.43 (+0.46%)
T   29.81 (-0.67%)
F   6.96 (+1.46%)
ACB   10.69 (-0.37%)
GILD   69.47 (-1.99%)
NFLX   503.86 (-1.13%)
DIS   128.25 (+9.34%)
BAC   25.35 (+1.36%)
BA   173.35 (+5.02%)
S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   437.34 (-0.30%)
MSFT   212.46 (-0.39%)
FB   249.95 (+0.05%)
GOOGL   1,480.47 (+0.49%)
AMZN   3,185.69 (+1.49%)
NVDA   450.97 (+0.41%)
CGC   19.17 (-0.78%)
BABA   264.03 (+0.70%)
TSLA   1,485.88 (-0.08%)
MU   50.98 (-0.62%)
GE   6.15 (+0.16%)
AMD   85.43 (+0.46%)
T   29.81 (-0.67%)
F   6.96 (+1.46%)
ACB   10.69 (-0.37%)
GILD   69.47 (-1.99%)
NFLX   503.86 (-1.13%)
DIS   128.25 (+9.34%)
BAC   25.35 (+1.36%)
BA   173.35 (+5.02%)
S&P 500   3,323.96 (+0.53%)
DOW   27,121.14 (+1.09%)
QQQ   270.67 (+0.11%)
AAPL   437.34 (-0.30%)
MSFT   212.46 (-0.39%)
FB   249.95 (+0.05%)
GOOGL   1,480.47 (+0.49%)
AMZN   3,185.69 (+1.49%)
NVDA   450.97 (+0.41%)
CGC   19.17 (-0.78%)
BABA   264.03 (+0.70%)
TSLA   1,485.88 (-0.08%)
MU   50.98 (-0.62%)
GE   6.15 (+0.16%)
AMD   85.43 (+0.46%)
T   29.81 (-0.67%)
F   6.96 (+1.46%)
ACB   10.69 (-0.37%)
GILD   69.47 (-1.99%)
NFLX   503.86 (-1.13%)
DIS   128.25 (+9.34%)
BAC   25.35 (+1.36%)
BA   173.35 (+5.02%)
Log in

NYSE:RLMDRelmada Therapeutics Stock Price, Forecast & News

$36.29
-1.10 (-2.94 %)
(As of 08/5/2020 12:48 PM ET)
Add
Compare
Today's Range
$35.90
Now: $36.29
$37.51
50-Day Range
$36.37
MA: $43.00
$49.98
52-Week Range
$8.08
Now: $36.29
$54.00
Volume2,543 shs
Average Volume161,538 shs
Market Capitalization$551.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone646-876-3459

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees4
Market Cap$551.54 million
Next Earnings Date9/22/2020 (Estimated)
OptionableOptionable
$36.29
-1.10 (-2.94 %)
(As of 08/5/2020 12:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Relmada Therapeutics (NYSE:RLMD) Frequently Asked Questions

How has Relmada Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RLMD stock has decreased by 9.7% and is now trading at $36.29.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Relmada Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Relmada Therapeutics
.

When is Relmada Therapeutics' next earnings date?

Relmada Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, September 22nd 2020.
View our earnings forecast for Relmada Therapeutics
.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NYSE:RLMD) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.39.
View Relmada Therapeutics' earnings history
.

Has Relmada Therapeutics been receiving favorable news coverage?

Media coverage about RLMD stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Relmada Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
View the latest news about Relmada Therapeutics
.

Who are some of Relmada Therapeutics' key competitors?

What other stocks do shareholders of Relmada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relmada Therapeutics investors own include Advanced Micro Devices (AMD), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Alteryx (AYX), Crispr Therapeutics (CRSP), Medtronic (MDT) and Micron Technology (MU).

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the following people:
  • Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO & Director (Age 60)
  • Dr. Ottavio V. Vitolo M.D., Sr. VP, Head of R&D and Chief Medical Officer (Age 48)
  • Mr. Charles S. Ence, Chief Financial Officer (Age 55)
  • Ms. Gina DiGuglielmo, VP & Head of Clinical Operations
  • Dr. Richard M. Mangano, Consultant (Age 70)

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "RLMD."

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $36.29.

How big of a company is Relmada Therapeutics?

Relmada Therapeutics has a market capitalization of $551.54 million. Relmada Therapeutics employs 4 workers across the globe.

What is Relmada Therapeutics' official website?

The official website for Relmada Therapeutics is www.relmada.com.

How can I contact Relmada Therapeutics?

The company can be reached via phone at 646-876-3459.

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.